E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Coronary Artery Disease/Angina |
|
E.1.1.1 | Medical condition in easily understood language |
Plaque build up and narrowing in heart arteries |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011078 |
E.1.2 | Term | Coronary artery disease |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10011073 |
E.1.2 | Term | Coronary artery atheroma |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002372 |
E.1.2 | Term | Angina |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003600 |
E.1.2 | Term | Atheroma coronary artery |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether Ivabradine, compared to standard therapy, will reduce the incidence and severity of PCI (percutaneous coronary intervention) related microvascular dysfunction/myocardial injury (subtle heart muscle injury) in patients with stable angina. |
|
E.2.2 | Secondary objectives of the trial |
To determine whether ivabradine improves coronary collateral blood flow, measured as collateral flow index, compared to standard therapy (beta blockers). Also to determine whether there is a reduction in peri-procedural cardiac troponin release (heart enzyme measure via blood test which indicates heart muscle damage) and/or improved coronary flow reserve (measure of blood flow to heart muscle on MRI) measured by cardiac magnetic resonance imaging. Finally also to determine whether any of these benefits translate into symptomatic improvements measured by exercise tolerance tests and angina symptom questionnaires. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. 1. Symptoms of Angina Pectoris 2. Angiographic evidence of epicardial coronary artery stenosis referred for PCI 3. Flow limiting lesion (Fractional Flow Reserve ≤0.80) in one of following locations (as defined in SYNTAX trial): a. Proximal or mid left anterior descending artery (LAD) b. Proximal or mid dominant right coronary artery (RCA) c. Proximal left circumflex artery (LCx) or 1ST Obtuse marginal Vessel 4. Existing beta blocker prescription 5. Echocardiogram performed within preceding 12 months 6. Patient consent
|
|
E.4 | Principal exclusion criteria |
1. 1. Previous myocardial infarction (MI) in target vessel myocardial territory or any MI in preceding 12 months (defined by patient history, ECG changes and evidence of regional wall motion abnormalities on echocardiography) 2. FFR>0.80 in target vessel at time of procedure 3. Requirement for Multi-vessel intervention in a single procedure 4. Any chronic total occlusion (100% epicardial occlusion) on angiography 5. Distal coronary artery stenosis or that affecting non-dominant RCA 6. Heart Rate <60 bpm at inclusion (assessed by 12 lead ECG after minimum 10 minutes rest period) 7. Any rhythm other than sinus rhythm 8. Sick sinus syndrome or high grade atrio-ventricular block 9. Permanent Pacemaker in situ 10. Congenital QT Syndrome 11. Intolerance or allergy to beta-blockers 12. Intolerance to Ivabradine 13. Additional (other than angina pectoris) indication for beta-blocker treatment e.g. ventricular tachycardia 14. Concurrent required use of rate-limiting drugs other than beta-blockers 15. The necessity of combination therapy with Ivabradine and bisoprolol to achieve heart rate control 16. Contraindication to Magnetic Resonance Imaging or IV adenosine 17. Severe impairment of renal function (eGFR<30ml/min) 18. Severe Liver Disease (Any worse than Grade A by Child-Pugh Classification)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Index of Microvascular Resistance (IMR) after PCI. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Immediately after the PCI stenting procedure. |
|
E.5.2 | Secondary end point(s) |
1. ΔIMR (difference in pre and post procedural IMR) 2. Peri-procedural troponin release (continuous variable) 3. CFI pre-revascularisation 4. Symptomatic improvement after revascularisation via Seattle questionnaire (in domains of angina frequency, stability and physical limitation) 5. Stress CMR measurement of coronary flow reserve in target vessel territory at 12 weeks post-procedure
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. immediately post procedure 2. 3 hours after PCI 3. Immediately before PCI 4. 12 weeks after procedure 5. 12 weeks after procedure |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 5 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 5 |